Please assess the completion status of the following clinical trial:

Trial Title: Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-Hodgkin's lymphoma (NHL) or multiple myoloma (MM) eligible for autologous transplantation~* No more than 3 prior regimens of chemotherapy~* More than 4 weeks since last cycle of chemotherapy. Patient recovered from all acute toxic effects of prior chemotherapy.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* White blood cell (WBC) count \>3.0\*10\^9/L~* Absolute polymorphonuclear cells (PMN) count \>1.5\*10\^9/L~* Platelet (PLT) count \>100\*10\^9/L~* Serum creatinine \<=2.2 mg/dL~* Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and total bilirubin \<2 x upper limit of normal (ULN)~* Left ventricle ejection fraction \>45% by normal echocardiogram or multiple-gated acquisition (MUGA) scan~* Negative for human immunodeficiency virus (HIV)~* Women of child bearing potential who agreed to use an approved form of contraception.~Exclusion Criteria:~* Patients who have failed previous collections~* Brain metastases or carcinomatous meningitis~* History of ventricular arrhythmias~* History of paresthesias~* A co-morbid condition which, in the view of the investigator, renders the patient at high risk for treatment complications~* A residual acute medical condition resulting from prior chemotherapy~* Acute infection~* Fever (temp \>38°C/100.4°F)~* Patients whose actual body weight exceeds 150% of their ideal body weight~* Patients who previously received experimental therapy within 4 weeks of enrolling in this study or who are currently enrolled in another experimental study during the mobilization period~* Positive pregnancy test in female patients~* Lactating females~* Patients of child-bearing potential unwilling to implement adequate birth control.~* Patients who have deterioration of their clinical status or laboratory parameters between the time of enrolment and transplant (such that they no longer meet entry criteria) may be removed from study at the discretion of the treating physician, principal investigator, or sponsor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Non-Hodgkin's Lymphoma (NHL) (Type: EXPERIMENTAL): Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
- Multiple Myeloma (MM) (Type: EXPERIMENTAL): Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete